Scancell Holdings (LSE:SCLP) Receivables Turnover: (As of Oct. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Scancell Holdings Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Scancell Holdings's Revenue for the six months ended in Oct. 2025 was £0.00 Mil. Scancell Holdings's average Accounts Receivable for the six months ended in Oct. 2025 was £0.00 Mil.

Scancell Holdings  (LSE:SCLP) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Scancell Holdings Receivables Turnover Related Terms

Scancell Holdings Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Receivables Turnover Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LSE:SCLP vs VRTX, REGN, MRNA: Receivables Turnover Comparison

For the Biotechnology subindustry, Scancell Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Receivables Turnover falls into.


Scancell Holdings Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Scancell Holdings's Receivables Turnover for the fiscal year that ended in Apr. 2025 is calculated as

Receivables Turnover (A: Apr. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Apr. 2025 ) / ((Accounts Receivable (A: Apr. 2024 ) + Accounts Receivable (A: Apr. 2025 )) / count )
=4.711 / (( + ) / 1 )
=4.711 / 0
=N/A

Scancell Holdings's Receivables Turnover for the quarter that ended in Oct. 2025 is calculated as

Receivables Turnover (Q: Oct. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Oct. 2025 ) / ((Accounts Receivable (Q: Apr. 2025 ) + Accounts Receivable (Q: Oct. 2025 )) / count )
=0 / (( + ) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Business Description

Other Exchanges SCNLF:USASCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.